Google Patentsopen access

Engineering of systems, methods and optimized guide compositions for sequence … — The Broad Institute, Inc. (US20250250553A1)

ABSTRACT

Abstract

The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR-Cas system.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/230,025, filed Aug. 5, 2016, which is a continuation of U.S. application Ser. No. 14/104,990, filed Dec. 12, 2013 and which claims priority to U.S. provisional patent application 61/836,127 entitled ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Jun. 17, 2013. This application also claims priority to U.S. provisional patent applications 61/758,468; 61/769,046; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130 each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on Jan. 30, 2013; Feb. 25, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013 respectively. Priority is also claimed to U.S. provisional patent applications 61/736,527 and 61/748,427, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Dec. 12, 2012 and Jan. 2, 2013, respectively. Priority is also claimed to U.S. provisional patent applications 61/791,409 and 61/835,931 both entitled BI-2011/008/44790.02.2003 and BI-2011/008/44790.03.2003 filed on Mar. 15, 2013 and Jun. 17, 2013 respectively.

Reference is also made to U.S. provisional patent applications 61/835,936, 61/836,101, 61/836,080, 61/836,123 and 61/835,973 each filed Jun. 17, 2013.

The foregoing applications, and all documents cited therein or during their prosecution (“appln cited documents”) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant number DP1MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention generally relates to systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Apr. 16, 2025, is named 114203-6217_SL and is 347,699 bytes in size.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention.

In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a cell, e.g., eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.

In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence is not necessary for CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes , or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

Aspects of the invention comprehend one or more of the guide, tracr and tracr mate sequences are modified to improve stability in the CRISPR-Cas system chiRNA or CRISPR enzyme system. In an embodiment of the invention, the modification may comprise sequence optimization. In another embodiment, the modification may comprise reduction in polyT sequences in the tracr and/or tracr mate sequence. The invention provides that one or more Ts present in a poly-T sequence of the relevant wild type sequence have been substituted with a non-T nucleotide. The modified sequence may not comprise any polyT sequence having more than 4 contiguous Ts. In a further aspect of the invention the modification may comprise altering loops and/or hairpins. Embodiments of the invention encompass providing a minimum of two hairpins in the guide sequence or providing a hairpin formed by complementation between the tracr and tracr mate sequence or providing one or more further hairpin(s) at the 3′ end of the tracrRNA sequence. Further embodiments of the invention encompass providing one or more additional hairpin(s) added to the 3′ of the guide sequence or extending the 5′ end of the guide sequence or providing one or more hairpins in the 5′ end of the guide sequence. In a preferred embodiment, the modification comprises two hairpins or three hairpins or at most five hairpins.

In general, and throughout this specification, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term “regulatory element” is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the 3-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.

In one aspect, the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising one or more nuclear localization sequences. In some embodiments, said regulatory element drives transcription of the CRISPR enzyme in a eukaryotic cell such that said CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell. In some embodiments, the regulatory element is a polymerase II promoter. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity.

In one aspect, the invention provides a CRISPR enzyme comprising one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme lacks the ability to cleave one or more strands of a target sequence to which it binds.

<div id="p-0019" num="

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/230,025, filed Aug. 5, 2016, which is a continuation of U.S. application Ser. No. 14/104,990, filed Dec. 12, 2013 and which claims priority to U.S. provisional patent application 61/836,127 entitled ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Jun. 17, 2013. This application also claims priority to U.S. provisional patent applications 61/758,468; 61/769,046; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130 each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on Jan. 30, 2013; Feb. 25, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013 respectively. Priority is also claimed to U.S. provisional patent applications 61/736,527 and 61/748,427, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Dec. 12, 2012 and Jan. 2, 2013, respectively. Priority is also claimed to U.S. provisional patent applications 61/791,409 and 61/835,931 both entitled BI-2011/008/44790.02.2003 and BI-2011/008/44790.03.2003 filed on Mar. 15, 2013 and Jun. 17, 2013 respectively.

Reference is also made to U.S. provisional patent applications 61/835,936, 61/836,101, 61/836,080, 61/836,123 and 61/835,973 each filed Jun. 17, 2013.

The foregoing applications, and all documents cited therein or during their prosecution (“appln cited documents”) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer&#39;s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant number DP1MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention generally relates to systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Apr. 16, 2025, is named 114203-6217_SL and is 347,699 bytes in size.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention.

In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a cell, e.g., eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; wherein components (a) and (b) are located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.

In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence is not necessary for CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes , or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

Aspects of the invention comprehend one or more of the guide, tracr and tracr mate sequences are modified to improve stability in the CRISPR-Cas system chiRNA or CRISPR enzyme system. In an embodiment of the invention, the modification may comprise sequence optimization. In another embodiment, the modification may comprise reduction in polyT sequences in the tracr and/or tracr mate sequence. The invention provides that one or more Ts present in a poly-T sequence of the relevant wild type sequence have been substituted with a non-T nucleotide. The modified sequence may not comprise any polyT sequence having more than 4 contiguous Ts. In a further aspect of the invention the modification may comprise altering loops and/or hairpins. Embodiments of the invention encompass providing a minimum of two hairpins in the guide sequence or providing a hairpin formed by complementation between the tracr and tracr mate sequence or providing one or more further hairpin(s) at the 3′ end of the tracrRNA sequence. Further embodiments of the invention encompass providing one or more additional hairpin(s) added to the 3′ of the guide sequence or extending the 5′ end of the guide sequence or providing one or more hairpins in the 5′ end of the guide sequence. In a preferred embodiment, the modification comprises two hairpins or three hairpins or at most five hairpins.

In general, and throughout this specification, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors.” Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term “regulatory element” is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the 3-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.

In one aspect, the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising one or more nuclear localization sequences. In some embodiments, said regulatory element drives transcription of the CRISPR enzyme in a eukaryotic cell such that said CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell. In some embodiments, the regulatory element is a polymerase II promoter. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity.

In one aspect, the invention provides a CRISPR enzyme comprising one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme lacks the ability to cleave one or more strands of a target sequence to which it binds.

In one aspect, the invention provides a eukaryotic host cell comprising (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotic cell. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the eukaryotic host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In an aspect, the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. In other aspects, the invention provides a eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. The organism in some embodiments of these aspects may be an animal; for example a mammal. Also, the organism may be an arthropod such as an insect. The organism also may be a plant. Further, the organism may be a fungus.

In one aspect, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes or S. thermophilus Cas9, and may include mutated Cas9 derived from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.

In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.

In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated with an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.

In one aspect, the invention provides a method for developing a biologically active agent that modulates a cell signaling event associated with a disease gene. In some embodiments, a disease gene is any gene associated with an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) contacting a test compound with a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or an augmentation of a cell signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.

In one aspect, the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a CRISPR complex to a corresponding target sequence present in a eukaryotic cell. In some embodiments, the target sequence is a viral sequence present in a eukaryotic cell. In some embodiments, the target sequence is a proto-oncogene or an oncogene.

In one aspect the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cell (s), the method comprising: introducing one or more vectors into the prokaryotic cell (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and a editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more prokaryotic cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRISPR enzyme is Cas9. In another aspect of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.

In some aspects the invention provides a non-naturally occurring or engineered composition comprising a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence wherein (a), (b) and (c) are arranged in a 5′ to 3′ orientation, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,

or

a CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) one or more guide sequences capable of hybridizing to one or more target sequences in a eukaryotic cell, (b) a tracr mate sequence, and (c) one or more tracr sequences, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5′ to 3′orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or a multiplexed CRISPR enzyme system, wherein the system is encoded by a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) one or more guide sequences capable of hybridizing to a target sequence in a cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and wherein in the multiplexed system multiple guide sequences and a single tracr sequence is used; and wherein one or more of the guide, tracr and tracr mate sequences are modified to improve stability.

In aspects of the invention, the modification comprises an engineered secondary structure. For example, the modification can comprise a reduction in a region of hybridization between the tracr mate sequence and the tracr sequence. For example, the modification also may comprise fusing the tracr mate sequence and the tracr sequence through an artificial loop. The modification may comprise the tracr sequence having a length between 40 and 120 bp. In embodiments of the invention, the tracr sequence is between 40 bp and full length of the tracr. In certain embodiments, the length of tracRNA includes at least nucleotides 1-67 and in some embodiments at least nucleotides 1-85 of the wild type tracRNA. In some embodiments, at least nucleotides corresponding to nucleotides 1-67 or 1-85 of wild type S. pyogenes Cas9 tracRNA may be used. Where the CRISPR system uses enzymes other than Cas9, or other than SpCas9, then corresponding nucleotides in the relevant wild type tracRNA may be present. In some embodiments, the length of tracRNA includes no more than nucleotides 1-67 or 1-85 of the wild type tracRNA. The modification may comprise sequence optimization. In certain aspects, sequence optimization may comprise reducing the incidence of polyT sequences in the tracr and/or tracr mate sequence. Sequence optimization may be combined with reduction in the region of hybridization between the tracr mate sequence and the tracr sequence; for example, a reduced length tracr sequence.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises reduction in polyT sequences in the tracr and/or tracr mate sequence. In some aspects of the invention, one or more Ts present in a poly-T sequence of the relevant wild type sequence (that is, a stretch of more than 3, 4, 5, 6, or more contiguous T bases; in some embodiments, a stretch of no more than 10, 9, 8, 7, 6 contiguous T bases) may be substituted with a non-T nucleotide, e.g., an A, so that the string is broken down into smaller stretches of Ts with each stretch having 4, or fewer than 4 (for example, 3 or 2) contiguous Ts. Bases other than A may be used for substitution, for example C or G, or non-naturally occurring nucleotides or modified nucleotides. If the string of Ts is involved in the formation of a hairpin (or stem loop), then it is advantageous that the complementary base for the non-T base be changed to complement the non-T nucleotide. For example, if the non-T base is an A, then its complement may be changed to a T, e.g., to preserve or assist in the preservation of secondary structure. For instance, 5′-TTTTT can be altered to become 5′-TTTAT and the complementary 5′-AAAAA can be changed into 5′-ATAAA.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence in tracr and/or tracr mate sequences. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises adding a polyT terminator sequence in the guide sequence. The polyT terminator sequence may comprise 5 contiguous T bases, or more than 5.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises altering loops and/or hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing a minimum of two hairpins in the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing a hairpin formed by complementation between the tracr and tracr mate (direct repeat) sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing one or more further hairpin(s) at or towards the 3′ end of the tracrRNA sequence. For example, a hairpin may be formed by providing self complementary sequences within the tracRNA sequence joined by a loop such that a hairpin is formed on self folding. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing additional hairpins added to the 3′ of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises extending the 5′ end of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing one or more hairpins in the 5′ end of the guide sequence. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises appending the sequence (5′-AGGACGAAGTCCTAA) (SEQ ID NO: 1) to the 5′ end of the guide sequence. Other sequences suitable for forming hairpins will be known to the skilled person, and may be used in certain aspects of the invention. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises two hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises three hairpins. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises at most five hairpins.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises providing cross linking, or providing one or more modified nucleotides in the polynucleotide sequence. Modified nucleotides and/or cross linking may be provided in any or all of the tracr, tracr mate, and/or guide sequences, and/or in the enzyme coding sequence, and/or in vector sequences. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2′-O-methyl analogs, 2′-deoxy analogs, or 2′-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.

It will be understood that any or all of the above modifications may be provided in isolation or in combination in a given CRISPR-Cas system or CRISPR enzyme system. Such a system may include one, two, three, four, five, or more of said modifications.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is a type II CRISPR system enzyme, e.g., a Cas9 enzyme. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is comprised of less than one thousand amino acids, or less than four thousand amino acids. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the Cas9 enzyme is StCas9 or St1Cas9, or the Cas9 enzyme is a Cas9 enzyme from an organism selected from the group consisting of genus Streptococcus, Campylobacter, Nitratifractor, Staphylococcus, Parvibaculum, Roseburia, Neisseria, Gluconacetobacter , Azospirillum, Sphaerochaeta, Lactobacillus, Eubacterium or Corynebacter . In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the first regulatory element is a polymerase III promoter. In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the second regulatory element is a polymerase II promoter.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the guide sequence comprises at least fifteen nucleotides.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the modification comprises optimized tracr sequence and/or optimized guide sequence RNA and/or co-fold structure of tracr sequence and/or tracr mate sequence(s) and/or stabilizing secondary structures of tracr sequence and/or tracr sequence with a reduced region of base-pairing and/or tracr sequence fused RNA elements; and/or, in the multiplexed system there are two RNAs comprising a tracer and comprising a plurality of guides or one RNA comprising a plurality of chimerics.

In aspects of the invention the chimeric RNA architecture is further optimized according to the results of mutagenesis studies. In chimeric RNA with two or more hairpins, mutations in the proximal direct repeat to stabilize the hairpin may result in ablation of CRISPR complex activity. Mutations in the distal direct repeat to shorten or stabilize the hairpin may have no effect on CRISPR complex activity. Sequence randomization in the bulge region between the proximal and distal repeats may significantly reduce CRISPR complex activity. Single base pair changes or sequence randomization in the linker region between hairpins may result in complete loss of CRISPR complex activity. Hairpin stabilization of the distal hairpins that follow the first hairpin after the guide sequence may result in maintenance or improvement of CRISPR complex activity. Accordingly, in preferred embodiments of the invention, the chimeric RNA architecture may be further optimized by generating a smaller chimeric RNA which may be beneficial for therapeutic delivery options and other uses and this may be achieved by altering the distal direct repeat so as to shorten or stabilize the hairpin. In further preferred embodiments of the invention, the chimeric RNA architecture may be further optimized by stabilizing one or more of the distal hairpins. Stabilization of hairpins may include modifying sequences suitable for forming hairpins. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. In some aspects of the invention stabilization may be cross linking and other modifications. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2′-O-methyl analogs, 2′-deoxy analogs, or 2′-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.

In an aspect the invention provides the CRISPR-Cas system or CRISPR enzyme system wherein the CRISPR enzyme is codon-optimized for expression in a eukaryotic cell.

Accordingly, in some aspects of the invention, the length of tracRNA required in a construct of the invention, e.g., a chimeric construct, need not necessarily be fixed, and in some aspects of the invention it can be between 40 and 120 bp, and in some aspects of the invention up to the full length of the tracr, e.g., in some aspects of the invention, until the 3′ end of tracr as punctuated by the transcription termination signal in the bacterial genome. In certain embodiments, the length of tracRNA includes at least nucleotides 1-67 and in some embodiments at least nucleotides 1-85 of the wild type tracRNA. In some embodiments, at least nucleotides corresponding to nucleotides 1-67 or 1-85 of wild type S. pyogenes Cas9 tracRNA may be used. Where the CRISPR system uses enzymes other than Cas9, or other than SpCas9, then corresponding nucleotides in the relevant wild type tracRNA may be present. In some embodiments, the length of tracRNA includes no more than nucleotides 1-67 or 1-85 of the wild type tracRNA With respect to sequence optimization (e.g., reduction in polyT sequences), e.g., as to strings of Ts internal to the tracr mate (direct repeat) or tracrRNA, in some aspects of the invention, one or more Ts present in a poly-T sequence of the relevant wild type sequence (that is, a stretch of more than 3, 4, 5, 6, or more contiguous T bases; in some embodiments, a stretch of no more than 10, 9, 8, 7, 6 contiguous T bases) may be substituted with a non-T nucleotide, e.g., an A, so that the string is broken down into smaller stretches of Ts with each stretch having 4, or fewer than 4 (for example, 3 or 2) contiguous Ts. If the string of Ts is involved in the formation of a hairpin (or stem loop), then it is advantageous that the complementary base for the non-T base be changed to complement the non-T nucleotide. For example, if the non-T base is an A, then its complement may be changed to a T, e.g., to preserve or assist in the preservation of secondary structure. For instance, 5′-TTTTT can be altered to become 5′-TTTAT and the complementary 5′-AAAAA can be changed into 5′-ATAAA. As to the presence of polyT terminator sequences in tracr+tracr mate transcript, e.g., a polyT terminator (TTTTT or more), in some aspects of the invention it is advantageous that such be added to end of the transcript, whether it is in two RNA (tracr and tracr mate) or single guide RNA form. Concerning loops and hairpins in tracr and tracr mate transcripts, in some aspects of the invention it is advantageous that a minimum of two hairpins be present in the chimeric guide RNA. A first hairpin can be the hairpin formed by complementation between the tracr and tracr mate (direct repeat) sequence. A second hairpin can be at the 3′ end of the tracrRNA sequence, and this can provide secondary structure for interaction with Cas9. Additional hairpins may be added to the 3′ of the guide RNA, e.g., in some aspects of the invention to increase the stability of the guide RNA. Additionally, the 5′ end of the guide RNA, in some aspects of the invention, may be extended. In some aspects of the invention, one may consider 20 bp in the 5′ end as a guide sequence. The 5′ portion may be extended. One or more hairpins can be provided in the 5′ portion, e.g., in some aspects of the invention, this may also improve the stability of the guide RNA. In some aspects of the invention, the specific hairpin can be provided by appending the sequence (5′-AGGACGAAGTCCTAA) (SEQ ID NO: 1) to the 5′ end of the guide sequence, and, in some aspects of the invention, this may help improve stability. Other sequences suitable for forming hairpins will be known to the skilled person, and may be used in certain aspects of the invention. In some aspects of the invention, at least 2, 3, 4, 5, or more additional hairpins are provided. In some aspects of the invention, no more than 10, 9, 8, 7, 6 additional hairpins are provided. The foregoing also provides aspects of the invention involving secondary structure in guide sequences. In some aspects of the invention there may be cross linking and other modifications, e.g., to improve stability. Modifications may include inclusion of at least one non naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2′-O-methyl analogs, 2′-deoxy analogs, or 2′-fluoro analogs. The nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used. The use of locked nucleic acids (LNA) or bridged nucleic acids (BNA) may also be possible. Further examples of modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine. Such modifications or cross linking may be present in the guide sequence or other sequences adjacent the guide sequence.

Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product.

It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIG. 1 shows a schematic model of the CRISPR system. The Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red). The guide sequence base-pairs with the DNA target (blue), directly upstream of a requisite 5′-NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double-stranded break (DSB) ˜3 bp upstream of the PAM (red triangle).

FIG. 2 A-F illustrates an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotic cells, and results of tests assessing nuclear localization and CRISPR activity. FIG. 2 C discloses SEQ ID NOS 103-104, respectively, in order of appearance. FIG. 2 E discloses SEQ ID NOS 105-107, respectively, in order of appearance. FIG. 2 F discloses SEQ ID NOS 108-112, respectively, in order of appearance.

FIG. 3 A-C illustrates an exemplary expression cassette for expression of CRISPR system elements in eukaryotic cells, predicted structures of example guide sequences, and CRISPR system activity as measured in eukaryotic and prokaryotic cells. FIG. 3 A discloses SEQ ID NO: 113. FIG. 3 B discloses SEQ ID NOS 114-122, respectively, in order of appearance.

FIG. 4 A-D illustrates results of an evaluation of SpCas9 specificity for an example target. FIG. 4 A discloses SEQ ID NOS 123, 106 and 124-134, respectively, in order of appearance. FIG. 4 C discloses SEQ ID NO: 123.

<div id="p-0050" n

CLAIMS

Claims ( 15 )

1 . (canceled)

2 . An engineered CRISPR-Cas system chimeric RNA comprising NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCA.

3 . The engineered CRISPR-Cas system chimeric RNA of claim 2 , wherein NNNNNNNNNNNNNNNNNNNN is a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell adjacent to a protospacer adjacent motif (PAM).

4 . The engineered CRISPR-Cas system chimeric RNA of claim 3 , wherein the PAM is NGG.

5 . The engineered CRISPR-Cas system chimeric RNA of claim 2 , further comprising a poly-U sequence.

6 . The engineered CRISPR-Cas system chimeric RNA of claim 2 , wherein the RNA sequence is encoded by SEQ ID NO:26.

7 . The engineered CRISPR-Cas system chimeric RNA of claim 2 , comprising one or more modified nucleotides.

8 . The engineered CRISPR-Cas system chimeric RNA of claim 2 , comprising one or more methylated nucleotides or nucleotide analogs.

9 . An engineered CRISPR-Cas system chimeric RNA comprising, from 5′ to 3′:

(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell adjacent to a protospacer adjacent motif (PAM),

(b) a tracr-mate sequence, and

(c) a tracr sequence comprising at least 40 nucleotides in length,

wherein the tracr-mate sequence is capable of hybridizing to the tracr sequence, and wherein the chimeric RNA is capable of forming a CRISPR complex with S. pyogenes Cas9 and directs sequence-specific binding of the CRISPR complex to the target sequence adjacent to the PAM in the eukaryotic cell.

10 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , wherein tracr sequence comprises at least 50 nucleotides in length.

11 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , wherein guide sequence comprises 15-25 nucleotides in length.

12 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , wherein the PAM is NGG.

13 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , further comprising a poly-U sequence.

14 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , comprising one or more modified nucleotides.

15 . The engineered CRISPR-Cas system chimeric RNA of claim 9 , comprising one or more methylated nucleotides or nucleotide analogs.

US19/025,692

2012-12-12

2025-01-16

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Pending

US20250250553A1

( en )

Priority Applications (1)

Application Number

Priority Date

Filing Date

Title

US19/025,692

US20250250553A1

( en )

2012-12-12

2025-01-16

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Applications Claiming Priority (15)

Application Number

Priority Date

Filing Date

Title

US201261736527P

2012-12-12

2012-12-12

US201361748427P

2013-01-02

2013-01-02

US201361758468P

2013-01-30

2013-01-30

US201361769046P

2013-02-25

2013-02-25

US201361791409P

2013-03-15

2013-03-15

US201361802174P

2013-03-15

2013-03-15

US201361806375P

2013-03-28

2013-03-28

US201361814263P

2013-04-20

2013-04-20

US201361819803P

2013-05-06

2013-05-06

US201361828130P

2013-05-28

2013-05-28

US201361836127P

2013-06-17

2013-06-17

US201361835931P

2013-06-17

2013-06-17

US14/104,990

US20140242664A1

( en )

2012-12-12

2013-12-12

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US15/230,025

US20160340662A1

( en )

2012-12-12

2016-08-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US19/025,692

US20250250553A1

( en )

2012-12-12

2025-01-16

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Related Parent Applications (1)

Application Number

Title

Priority Date

Filing Date

US15/230,025

Continuation

US20160340662A1

( en )

2012-12-12

2016-08-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Publications (1)

Publication Number

Publication Date

US20250250553A1

true

US20250250553A1 ( en )

2025-08-07

Family

ID=49920627

Family Applications (6)

Application Number

Title

Priority Date

Filing Date

US14/104,990

Abandoned

US20140242664A1

( en )

2012-12-12

2013-12-12

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/290,575

Active

US8906616B2

( en )

2012-12-12

2014-05-29

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/703,511

Pending

US20150232882A1

( en )

2012-12-12

2015-05-04

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/704,551

Pending

US20150247150A1

( en )

2012-12-12

2015-05-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US15/230,025

Pending

US20160340662A1

( en )

2012-12-12

2016-08-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US19/025,692

Pending

US20250250553A1

( en )

2012-12-12

2025-01-16

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Family Applications Before (5)

Application Number

Title

Priority Date

Filing Date

US14/104,990

Abandoned

US20140242664A1

( en )

2012-12-12

2013-12-12

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/290,575

Active

US8906616B2

( en )

2012-12-12

2014-05-29

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/703,511

Pending

US20150232882A1

( en )

2012-12-12

2015-05-04

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US14/704,551

Pending

US20150247150A1

( en )

2012-12-12

2015-05-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

US15/230,025

Pending

US20160340662A1

( en )

2012-12-12

2016-08-05

Engineering of systems, methods and optimized guide compositions for sequence manipulation

Country Status (16)

Country

Link

US

( 6 )

US20140242664A1

( en )

EP

( 3 )

EP2771468B1

( en )

JP

( 11 )

JP2016504026A

( en )

KR

( 1 )

KR20150105633A

( en )

CN

( 3 )

CN113528577B

( en )

AU

( 5 )

AU2013359123B2

( en )

CA

( 1 )

CA2894701A1

( en )

DK

( 1 )

DK2771468T3

( en )

ES

( 4 )

ES2536353T3

( en )

HK

( 1 )

HK1210221A1

( en )

IL

( 2 )

IL239344B2

( en )

MX

( 1 )

MX380562B

( en )

PL

( 2 )

PL2771468T3

( en )

PT

( 4 )

PT2896697E

( en )

RU

( 1 )

RU2701850C2

( en )

WO

( 1 )

WO2014093712A1

( en )

Families Citing this family (749)

* Cited by examiner, † Cited by third party

Publication number

Priority date

Publication date

Assignee

Title

WO2011140441A2

( en )

2010-05-06

2011-11-10

Children&#39;s Hospital Medical Center

Methods and systems for converting precursor cells into intestinal tissues through directed differentiation

EP2689019A2

( en )

2011-03-23

2014-01-29

Pioneer Hi-Bred International Inc.

Methods for producing a complex transgenic trait locus

WO2013066438A2

( en )

2011-07-22

2013-05-10

President And Fellows Of Harvard College

Evaluation and improvement of nuclease cleavage specificity

EP3604555B1

( en )

2011-10-14

2024-12-25

President and Fellows of Harvard College

Sequencing by structure assembly

WO2014163886A1

( en )

2013-03-12

2014-10-09

President And Fellows Of Harvard College

Method of generating a three-dimensional nucleic acid containing matrix

ES2991004T3

( en )

2011-12-22

2024-12-02

Harvard College

Methods for the detection of analytes

GB201122458D0

( en )

2011-12-30

2012-02-08

Univ Wageningen

Modified cascade ribonucleoproteins and uses thereof

US9637739B2

( en )

*

2012-03-20

2017-05-02

Vilnius University

RNA-directed DNA cleavage by the Cas9-crRNA complex

RU2645475C2

( en )

2012-04-25

2018-02-21

Регенерон Фармасьютикалз, Инк.

Nuclease-mediated targeting with large targeting vectors

WO2013163628A2

( en )

2012-04-27

2013-10-31

Duke University

Genetic correction of mutated genes

LT3401400T

( en )

2012-05-25

2019-06-10

The Regents Of The University Of California

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

US20150225734A1

( en )

2012-06-19

2015-08-13

Regents Of The University Of Minnesota

Gene targeting in plants using dna viruses

CA2875618C

( en )

2012-07-11

2021-04-27

Sangamo Biosciences, Inc.

Methods and compositions for the treatment of lysosomal storage diseases

US10648001B2

( en )

2012-07-11

2020-05-12

Sangamo Therapeutics, Inc.

Method of treating mucopolysaccharidosis type I or II

JP2015527889A

( en )

*

2012-07-25

2015-09-24

ザ ブロード インスティテュート， インコーポレイテッド

Inducible DNA binding protein and genomic disruption tools and their applications

JP6367196B2

( en )

2012-08-14

2018-08-01

テンエックス・ジェノミクス・インコーポレイテッド

Microcapsule composition and method

US9951386B2

( en )

2014-06-26

2018-04-24

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US10752949B2

( en )

2012-08-14

2020-08-25

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US11591637B2

( en )

2012-08-14

2023-02-28

10X Genomics, Inc.

Compositions and methods for sample processing

US9701998B2

( en )

2012-12-14

2017-07-11

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US10584381B2

( en )

2012-08-14

2020-03-10

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US10273541B2

( en )

2012-08-14

2019-04-30

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US10323279B2

( en )

2012-08-14

2019-06-18

10X Genomics, Inc.

Methods and systems for processing polynucleotides

PL4397760T3

( en )

2012-10-23

2026-03-30

Toolgen Incorporated

A COMPOSITION FOR CLEFULNING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR A TARGET DNA AND A NUCLEIC ACID ENCODING A CAS PROTEIN OR A CAS PROTEIN, AND USE THEREOF

AU2013352156B2

( en )

2012-11-27

2018-12-06

Children&#39;s Medical Center Corporation

Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction

EP3135765A1

( en )

2012-12-06

2017-03-01

Sigma-Aldrich Co. LLC

Crispr-based genome modification and regulation

US8697359B1

( en )

2012-12-12

2014-04-15

The Broad Institute, Inc.

CRISPR-Cas systems and methods for altering expression of gene products

EP2896697B1

( en )

2012-12-12

2015-09-02

The Broad Institute, Inc.

Engineering of systems, methods and optimized guide compositions for sequence manipulation

ES2576126T3

( en )

2012-12-12

2016-07-05

The Broad Institute, Inc.

Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation

JP2016504026A

( en )

*

2012-12-12

2016-02-12

ザ・ブロード・インスティテュート・インコーポレイテッド

Engineering systems, methods and optimization guide compositions for sequence manipulation

IL239317B

( en )

2012-12-12

2022-07-01

Broad Inst Inc

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

EP3434776A1

( en )

2012-12-12

2019-01-30

The Broad Institute, Inc.

Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof

CN114634950A

( en )

2012-12-12

2022-06-17

布罗德研究所有限公司

CRISPR-CAS component systems, methods, and compositions for sequence manipulation

EP2931898B1

( en )

2012-12-12

2016-03-09

The Broad Institute, Inc.

Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains

WO2014093701A1

( en )

2012-12-12

2014-06-19

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof

EP3567116A1

( en )

2012-12-14

2019-11-13

10X Genomics, Inc.

Methods and systems for processing polynucleotides

US10533221B2

( en )

2012-12-14

2020-01-14

10X Genomics, Inc.

Methods and systems for processing polynucleotides

SG10201912991WA

( en )

*

2012-12-17

2020-03-30

Harvard College

Rna-guided human genome engineering

EP3919505B1

( en )

2013-01-16

2023-08-30

Emory University

Uses of cas9-nucleic acid complexes

KR102190198B1

( en )

2013-02-08

2020-12-14

10엑스 제노믹스, 인크.

Polynucleotide barcode generation

SG11201507378UA

( en )

2013-03-14

2015-10-29

Caribou Biosciences Inc

Compositions and methods of nucleic acid-targeting nucleic acids

US10760064B2

( en )

2013-03-15

2020-09-01

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

WO2014204578A1

( en )

2013-06-21

2014-12-24

The General Hospital Corporation

Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing

US9234213B2

( en )

2013-03-15

2016-01-12

System Biosciences, Llc

Compositions and methods directed to CRISPR/Cas genomic engineering systems

US10378027B2

( en )

2013-03-15

2019-08-13

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

US20140273235A1

( en )

*

2013-03-15

2014-09-18

Regents Of The University Of Minnesota

ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS

US9828582B2

( en )

2013-03-19

2017-11-28

Duke University

Compositions and methods for the induction and tuning of gene expression

JP2016522679A

( en )

2013-04-04

2016-08-04

プレジデント アンド フェローズ オブ ハーバード カレッジ

Therapeutic use of genome editing with the CRISPR / Cas system

DK2986729T3

( en )

2013-04-16

2018-10-29

Regeneron Pharma

TARGETED MODIFICATION OF ROOT THROUGH

SG10201710030QA

( en )

2013-06-04

2018-01-30

Harvard College

Rna-guided transcriptional regulation

US20140356956A1

( en )

2013-06-04

2014-12-04

President And Fellows Of Harvard College

RNA-Guided Transcriptional Regulation

JP6665088B2

( en )

2013-06-17

2020-03-13

ザ・ブロード・インスティテュート・インコーポレイテッド

Optimized CRISPR-Cas double nickase system, method and composition for sequence manipulation

CN105793425B

( en )

2013-06-17

2021-10-26

布罗德研究所有限公司

Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components

EP3725885A1

( en )

2013-06-17

2020-10-21

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof

WO2014204724A1

( en )

2013-06-17

2014-12-24

The Broad Institute Inc.

Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation

MX2015017312A

( en )

2013-06-17

2017-04-10

Broad Inst Inc

SUPPLY AND USE OF CRISPR-CAS COMPOSITIONS, VECTORS AND SYSTEMS FOR DIRECTED MODIFICATION AND HEPATIC THERAPY.

EP3738545B1

( en )

2013-06-19

2023-11-29

Kolibree

Toothbrush system with sensors for a dental hygiene monitoring system

JP2016528890A

( en )

2013-07-09

2016-09-23

プレジデント アンド フェローズ オブ ハーバード カレッジ

Therapeutic use of genome editing using the CRISPR / Cas system

HUE056760T2

( en )

*

2013-07-11

2022-03-28

Modernatx Inc

Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use

US20150044192A1

( en )

2013-08-09

2015-02-12

President And Fellows Of Harvard College

Methods for identifying a target site of a cas9 nuclease

US9359599B2

( en )

2013-08-22

2016-06-07

President And Fellows Of Harvard College

Engineered transcription activator-like effector (TALE) domains and uses thereof

CA3221516A1

( en )

2013-08-22

2015-02-26

E. I. Du Pont De Nemours And Company

Plant genome modification using guide rna/cas endonuclease systems and methods of use

US9388430B2

( en )

2013-09-06

2016-07-12

President And Fellows Of Harvard College

Cas9-recombinase fusion proteins and uses thereof

US9526784B2

( en )

2013-09-06

2016-12-27

President And Fellows Of Harvard College

Delivery system for functional nucleases

US9340799B2

( en )

2013-09-06

2016-05-17

President And Fellows Of Harvard College

MRNA-sensing switchable gRNAs

ES2844174T3

( en )

2013-09-18

2021-07-21

Kymab Ltd

Methods, cells and organisms

WO2015054507A1

( en )

2013-10-10

2015-04-16

Pronutria, Inc.

Nutritive polypeptide production systems, and methods of manufacture and use thereof

WO2015065964A1

( en )

2013-10-28

2015-05-07

The Broad Institute Inc.

Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof

CN106459995B

( en )

2013-11-07

2020-02-21

爱迪塔斯医药有限公司

CRISPR-related methods and compositions using dominant gRNAs

WO2015088643A1

( en )

2013-12-11

2015-06-18

Regeneron Pharmaceuticals, Inc.

Methods and compositions for the targeted modification of a genome

US20150166984A1

( en )

2013-12-12

2015-06-18

President And Fellows Of Harvard College

Methods for correcting alpha-antitrypsin point mutations

WO2015089364A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Crystal structure of a crispr-cas system, and uses thereof

BR112016013547A2

( en )

2013-12-12

2017-10-03

Broad Inst Inc

COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS

RU2016128077A

( en )

2013-12-12

2018-12-06

Те Брод Инститьют Инк.

DELIVERY, APPLICATION AND APPLICATIONS IN THE THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TREATMENT OF CONDITIONED HBV AND VIRAL DISEASES AND DISORDERS

WO2015089427A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes

WO2015089486A2

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems

CN111206032B

( en )

2013-12-12

2024-07-19

布罗德研究所有限公司

Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing

BR112016013213A2

( en )

2013-12-12

2017-12-05

Massachusetts Inst Technology

administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components

WO2015089473A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation

EP4063503A1

( en )

2014-02-11

2022-09-28

The Regents of the University of Colorado, a body corporate

Crispr enabled multiplexed genome engineering

EP3107999A4

( en )

2014-02-18

2017-10-04

Duke University

Compositions for the inactivation of virus replication and methods of making and using the same

EP3971283A1

( en )

2014-02-27

2022-03-23

Monsanto Technology LLC

Compositions and methods for site directed genomic modification

WO2015130968A2

( en )

2014-02-27

2015-09-03

The Broad Institute Inc.

T cell balance gene expression, compositions of matters and methods of use thereof

EP3115457B1

( en )

2014-03-05

2019-10-02

National University Corporation Kobe University

Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same

US11028388B2

( en )

2014-03-05

2021-06-08

Editas Medicine, Inc.

CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa

US11141493B2

( en )

2014-03-10

2021-10-12

Editas Medicine, Inc.

Compositions and methods for treating CEP290-associated disease

US11339437B2

( en )

2014-03-10

2022-05-24

Editas Medicine, Inc.

Compositions and methods for treating CEP290-associated disease

CA2948728A1

( en )

2014-03-10

2015-09-17

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating leber&#39;s congenital amaurosis 10 (lca10)

JP6815986B2

( en )

2014-03-26

2021-01-20

ユニバーシティ オブ メリーランド， カレッジ パーク

Targeted genome editing in zygotes of large livestock

WO2015148863A2

( en )

2014-03-26

2015-10-01

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating sickle cell disease

EP3498845B1

( en )

*

2014-04-01

2022-06-22

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)

EP3126495A1

( en )

2014-04-02

2017-02-08

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating primary open angle glaucoma

CA2943624A1

( en )

2014-04-10

2015-10-15

10X Genomics, Inc.

Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same

ES2744186T3

( en )

2014-04-25

2020-02-24

Childrens Medical Center

Compositions and methods to treat hemoglobinopathies

EP3712254A1

( en )

2014-05-28

2020-09-23

Children&#39;s Hospital Medical Center

Methods and systems for converting precursor cells into gastric tissues through directed differentiation

KR20170005494A

( en )

2014-05-30

2017-01-13

더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티

Compositions and methods of delivering treatments for latent viral infections

EP3154694B1

( en )

2014-06-13

2025-01-29

Children&#39;s Medical Center Corporation

Products and methods to isolate mitochondria

EP3919621A1

( en )

2014-06-23

2021-12-08

The General Hospital Corporation

Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)

WO2015200555A2

( en )

*

2014-06-25

2015-12-30

Caribou Biosciences, Inc.

Rna modification to engineer cas9 activity

WO2015200869A1

( en )

2014-06-26

2015-12-30

10X Genomics, Inc.

Analysis of nucleic acid sequences

US12312640B2

( en )

2014-06-26

2025-05-27

10X Genomics, Inc.

Analysis of nucleic acid sequences

EP4574974A3

( en )

2014-06-26

2025-10-08

10x Genomics, Inc.

Methods of analyzing nucleic acids from individual cells or cell populations

CN106687594A

( en )

2014-07-11

2017-05-17

纳幕尔杜邦公司

Compositions and methods for producing plants resistant to glyphosate herbicide

US10179932B2

( en )

2014-07-11

2019-01-15

President And Fellows Of Harvard College

Methods for high-throughput labelling and detection of biological features in situ using microscopy

WO2016022363A2

( en )

2014-07-30

2016-02-11

President And Fellows Of Harvard College

Cas9 proteins including ligand-dependent inteins

CN104195177B

( en )

*

2014-08-05

2017-06-09

南京大学

A kind of method for significantly improving Fish genomes editorial efficiency

<tr itemprop="forwardReferencesFami

Related documents

• Virtual reality system using multiple force arrays for a solver — DeepMotion, Inc. (US10657696B2)#653961
• Augmented reality system with spatialized audio tied to user manipulated … — Magic Leap, Inc. (US11231770B2)#653963
• High-efficiency fuel cell system with carbon dioxide capture assembly and … — Fuelcell Energy, Inc. (US10170782B2)#653965
• Integrated electrochemical cell power generation and electrolysis systems — Czero, Inc. (US20250087711A1)#653966
• Generating augmented reality experiences utilizing physical objects to … — Meta Platforms Technologies, Llc (US20260037214A1)#653960